David Meeker may be leaving Sanofi Genzyme after a long run at the big Boston operation, but he’s staying in biotech.
Meeker recently announced his retirement from the Sanofi subsidiary, effective in June, and today he’s taking the chairman’s role at Rhythm, a Boston-based startup that is developing peptide therapies for rare genetic conditions.
Meeker is following a path blazed by former boss Henri Termeer, who followed the $20 billion sale of Genzyme with a high-profile role seeding biotech startups and serving on a variety of boards in the hot life sciences hub.
Keith Gottesdiener, the CEO at Rhythm, says he’s planning to tap Meeker for some insights on commercializing drugs for rare diseases. And Meeker says he’s excited by this new chapter in his career.
“This is an exciting time at Rhythm as the company seeks to address some of the genetic causes of obesity, an area where there is significant unmet medical need and our understanding of the science is beginning to emerge,” said Meeker in a statement.
Prominent biotech execs don’t really retire. They just wait a bit for the phone to ring.
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.